Allurion Technologies announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office for patents related to its next-generation gastric balloon technology for obesity treatment. The patents issued are U.S. Patent No. 12,246,163 for an “Automatic-Sealing Balloon-Filling Catheter System” and U.S. Patent No. 12,245,962 for a “Balloon Sealing and Fill Valve.” These patents cover enhancements to Allurion’s proprietary balloon technology, including an improved valve system and a new mechanism to regulate balloon opening. It is anticipated that the patents will continue to be protected until April 2043. With these additions, Allurion now holds 22 U.S. patents and 64 patents worldwide.
The Allurion Program combines the Allurion Gastric Balloon—the only swallowable, procedure-less gastric balloon—with a digital support system that includes the Allurion Mobile App, Connected Scale, and Allurion Insights platform featuring Iris AI for healthcare providers. The program has been shown to help patients lose 10-15 percent of their total body weight, with some studies also reporting increases in muscle mass. Shantanu Gaur, Allurion’s Founder and CEO, said, “With the issuance of these two patents, we now have amassed 22 issued patents in the U.S. and 64 issued patents globally. As we embark on new clinical trials that seek to combine the Allurion Balloon with GLP-1 therapy, we intend to continuously enhance the design and manufacture of the Allurion Balloon and move toward a new gold standard for the treatment of obesity.”
